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COMMENTARIES

Extensively Drug-Resistant Tuberculosis
An Isolation Order, Public Health Powers, and a Global Crisis
Howard Markel, MD, PhD
Lawrence O. Gostin, JD
David P. Fidler, JD

C

ENTURIES AFTER THE FORMAL CREATION OF QUARantine, the practice continues to evoke concern
when implemented to halt the spread of dangerous microbes. Witness the controversy generated by US citizen Andrew Speaker, whom the US Centers
for Disease Control and Prevention (CDC) detained and isolated because he was diagnosed with pulmonary disease
caused by extensively drug-resistant tuberculosis (XDRTB). Speaker’s case made compelling news, but it also raised
questions about the emergence of XDR-TB, the adequacy
of public health powers in the United States, and the international dimensions of the XDR-TB threat.

The Recent Encounter With XDR-TB
According to media reports,1-3 congressional testimony,4 and
official reports,5 physicians diagnosed Speaker with pulmonary TB in March 2007. He was prescribed a regimen of standard anti-TB medications. Susceptibility testing determined that Speaker’s TB was multidrug resistant, which
prompted county public health authorities to advise Speaker
orally on May 10 not to travel but to consider specialized
treatment. Instead, Speaker advanced his travel by 48 hours
and flew from Atlanta, Georgia, to Paris, France, on May
12. From May 11 through 13, county public health officials tried to deliver written notice to Speaker that travel
would be against medical advice and would risk harming
others’ health. On May 22, the CDC confirmed that Speaker
had XDR-TB.
Speaker’s wedding and honeymoon took him to Greece
and then Rome, where the CDC contacted him by telephone on May 22 to inform him that he had XDR-TB, should
not travel further on commercial airlines, and should report to Italian health authorities while US officials pursued
options for his return home. Instead, Speaker flew to Prague, then to Montreal, Canada, and then drove into the
United States.
Although the CDC placed Speaker’s name on a health surveillance list, a US border guard allowed Speaker into the
United States despite seeing the CDC’s warning.1 Once in
the country, CDC located Speaker, instructed him to re©2007 American Medical Association. All rights reserved.

port to Bellevue Hospital in New York City, New York, and
indicated that failure to do so would violate federal quarantine law. After 72 hours at Bellevue under a provisional
isolation order, Speaker was transported by the CDC to Atlanta and a federal isolation order was issued against him.
This order was the first such federal order since a suspected smallpox carrier was quarantined in 1963.6 Speaker’s travels forced the CDC and other public health authorities from multiple countries to try to locate hundreds of airline
passengers who may have been exposed to XDR-TB. Later,
Speaker was transferred under escort by a CDC quarantine
officer to the National Jewish Medical Center in Denver,
Colorado, for treatment.
The Emergence of the XDR-TB Problem
Media coverage of Speaker’s situation provided many people
with an introduction to XDR-TB, which is the latest chapter
in humanity’s battle with the “white plague.” Once thought
under control in developed countries, TB cases increased in
the 1980s after funding cuts for TB prevention and treatment programs and the emergence of the AIDS pandemic.
The reemergence of TB had the harshest consequences in the
developing world, particularly with the impact of HIV/AIDS
on susceptibility to TB infection. The increase in TB cases led
to an increase in inadequate or incomplete antibiotic treatments, which produced resistant TB strains.7
Multidrug-resistant TB (MDR-TB) arose during this period and includes TB strains that are resistant to at least 2
of the most commonly prescribed anti-TB drugs: isoniazid
and rifampin. MDR-TB often appears when a patient takes
an incomplete course of anti-TB medications or is acquired
during exposure to air shared with other persons harboring MDR-TB, if infection control precautions are not implemented or are inadequate. But XDR-TB is more problematic because it is also resistant to any fluoroquinolone and
at least 1 of the 3 second-line drugs: capreomycin, kanamycin, and amikacin.8
Surveillance data on XDR-TB are still rudimentary, but
even with incomplete information, public health officials are
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alarmed. XDR-TB has appeared in many countries, including the United States, and is of particular concern in Eastern Europe, South Africa, and Asia.9 The issuance in 2006
by the World Health Organization (WHO) of a global alert
about XDR-TB10 underscores the harsh reality that XDR-TB
has the potential to transform a once treatable infection into
an infectious disease as deadly, if not more so, than TB at
the beginning of the 20th century.
XDR-TB and Quarantine
Speaker’s isolation has focused attention on the exercise of
public health powers, especially with respect to quarantine
and isolation at the local, state, federal, and international
levels. Definitions of quarantine have changed over the centuries, but so too have political, legal, and cultural frames
of reference.
For most of the history of quarantine, the biggest concerns related to lost commerce caused by closing ports or
cities to goods and travelers. During many historical eras,
governments sometimes abused quarantine powers by applying them against socially undesirable segments of populations perceived to be sickly or contagious.11 In other periods, quarantine has been contested for political and
nationalistic reasons. More recently, the perceived conflict
between individual rights and public health has dominated
quarantine debates. This trend has been strongest in democratic nations that emphasize civil liberties. Each frame of
reference remains important, which highlights the need to
understand how the law authorizes governments to engage
in quarantine activities.11
Legal Authority for Isolation and Quarantine
in the United States
The Complexity of Quarantine Law. Legal authority for public health powers, including isolation and quarantine, exists at local, state, and federal levels. This situation produces problems related to federalism: Which level of
government may act? Which laws apply, and in what circumstances? Theoretically, local and state law addresses
threats confined to a single city, county, or state; federal law
applies to diseases arriving from foreign countries or being
transmitted across state lines.
Behind that theory lies a complex problem regarding the
“lead” government official in any given situation. Public
health emergencies require clear lines of authority, and the
Speaker case illustrates some breakdowns in this respect:
county public health officials were allegedly not clear in their
instructions to Speaker because they told him not to travel
but that he did not pose a risk to others; and a federal border guard let Speaker into the United States despite being
aware of CDC’s notification that Speaker should be detained.1
State Quarantine Authority. State authority to compel
isolation and quarantine derives from the police power (Gibbons v Ogden, 22 US 1, 25 [1824]). Although all states have
84
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authorized isolation and quarantine, these laws vary considerably. Often, different approaches are not a problem, but
variation could prevent or delay effective responses to a multistate emergency. Disparate legal structures can also undermine cooperation among state and federal officials. In
addition, state quarantine laws are often old and do not reflect contemporary scientific understandings of disease or
changes in the protection of civil liberties.
In light of recent threats, states have begun to reconsider
quarantine authority within their emergency response systems. The president urged states to review their quarantine
authorities as a homeland security priority,12 and 38 states
have adopted, in whole or in part, the Model State Emergency Health Powers Act (MSEHPA). Drafted in response
to the 2001 anthrax attacks, the MSEHPA requires the state’s
governor to declare an emergency before special quarantine powers are exercised.13 The “Turning Point” Model State
Public Health Act, drafted in 2003, provides a range of public health powers that do not require an emergency declaration, but few states have used this model act to revise their
laws.14 The Speaker case will, again, encourage state governments to revisit their quarantine laws.
Federal Quarantine Authority. Federal quarantine authority grants the secretary of the US Department of Health
and Human Services the power to issue regulations to prevent the introduction, transmission, or interstate spread of
communicable diseases into or within the United States and
to apprehend, detain, or conditionally release individuals
infected with “quarantinable diseases” specified by executive order.15 Infectious TB is a quarantinable disease.16
The Speaker case illustrates weaknesses in federal quarantine authority. First, federal powers apply only to a small
number of diseases, depriving the CDC of flexibility to respond to novel threats. For a new threat, the president must
issue an executive order making the disease quarantinable,
as happened with SARS (severe acute respiratory syndrome) and pandemic influenza. Second, federal rules do
not authorize a range of powers, including screening, contact tracing, and directly observed therapy, which may be
needed to address certain threats, including XDR-TB. Third,
federal quarantine law lacks adequate due process protections because it does not give affected individuals a right to
a fair hearing. Given constitutional requirements for an impartial hearing for anyone under civil detention or confinement,17 including people with TB,18 federal quarantine powers are arguably unconstitutional.
Proposed Revisions to the Federal Quarantine Regulations.
Recognizing these problems, the Department of Health and
Human Services proposed new regulations in late 2005.19
The proposed rules would expand the scope of federal power
by defining “ill person” to include those with signs or symptoms commonly associated with quarantinable diseases (eg,
fever, rash, persistent cough, or diarrhea), thus affording CDC
greater flexibility. The proposed regulations would require
airlines and other carriers to screen passengers at borders;
©2007 American Medical Association. All rights reserved.
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report cases of illness or death to the CDC; distribute health
alert notices to crew and passengers; collect and transmit
personal passenger information; order physical examination of exposed persons; and require passengers to disclose
information about their contacts, travel itinerary, and medical history. The proposed rules also build more due process protections into federal quarantine law, protections the
CDC included in Speaker’s isolation order (ie, a right to a
hearing, which Speaker decided not to pursue4).
The revisions to federal quarantine regulations proved controversial and have not yet been adopted. Although the public health community welcomed many proposed changes,
those concerned with potential invasions of liberty, privacy, and property criticized aspects of the proposal. The
travel industry complained about the costs imposed on it
to collect passenger data. Civil libertarians argued that the
new rules would not protect privacy adequately. Due process advocates criticized the proposal for providing no right
to a hearing for “provisional” quarantines lasting up to 3
business days. In addition, the proposal did not address all
concerns about due process requirements for full quarantine measures because it required quarantined individuals
to request a hearing, provided for informal proceedings, and
permitted a CDC employee to preside over the hearing rather
than an impartial tribunal.
Speaker’s case has drawn attention to the future application of quarantine powers by the federal government with
respect to XDR-TB. As with other disease threats, public
health officials need a range of powers, but they must exercise those powers fairly and in accordance with the rule
of law. XDR-TB may test the ability of governments in the
United States to balance public health and individual rights.
International Dimensions
Speaker’s odyssey also reveals the international dimensions of XDR-TB, which highlight questions about how the
United States exercises public health powers in a global context, how international law applies to XDR-TB, and what
strategies exist to address the global XDR-TB crisis.
Travel Restrictions on Persons Leaving the United States.
Speaker’s case raises questions about the government’s ability to prevent a person who poses a health risk from leaving the United States. County officials orally advised Speaker
not to travel, but what government body could have prevented him from traveling to Europe? Given the international context, the federal government is the relevant constitutional authority. Federal law focuses, however, on
preventing disease importation and does not mention preventing disease exportation.15 Neither statutory law nor existing or proposed federal quarantine regulations address
the need to prevent persons in the United States who pose
a health risk from leaving the country.
Extrajurisdictional Application of US Public Health Law.
The CDC advised Speaker to report to Italian authorities,
but he did not follow this advice.4,5 This raises the question
©2007 American Medical Association. All rights reserved.

of whether the United States can enforce federal quarantine orders on US citizens in other countries. Federal law
does not apply outside the United States unless Congress
intends for it to so apply.20 Congress expressed no such intent in federal public health law, prescribing that federal quarantine regulations “for the apprehension, detention, examination, or conditional release of individuals, shall be
applicable only to individuals coming into a State or possession from a foreign country or a possession.”15
Screening for Public Health Threats at US Borders. Speaker’s entry into the United States focuses attention on screening for health threats at US borders. Unlike Speaker’s situation, the typical problems concern the failure or inability
of border control systems to identify health threats. These
problems point to weaknesses in the system of quarantine
stations at US ports of entry. According to an Institute of
Medicine study, the small number of and traditional activities undertaken by quarantine stations “no longer protect
the US population against microbial threats of public health
significance that originate abroad.”21 This study recommended improvements in leadership, legal authorities, infrastructure, training, funding, and collaboration to improve the federal government’s ability to prevent disease
importation. Speaker’s case suggests that, despite improvements, work remains to be done in this area.
XDR-TB and the New International Health Regulations.
Speaker’s case also raises broader concerns about the role
of international law in addressing XDR-TB. Here, the new
International Health Regulations, adopted in May 2005 and
entered into force on June 15, 2007 (IHR 2005),22 deserve
attention. First, public health reactions to Speaker’s travels
demonstrate that XDR-TB cases may constitute public health
emergencies of international concern that must be notified
to WHO under the IHR 2005.22 As illustrated by the Speaker
episode, XDR-TB cases could satisfy the criteria of the IHR
2005 for determining whether an event may constitute a public health emergency of international concern . The United
States notified WHO about the Speaker case on May 24 despite the IHR 2005 not being in force. An obligation to report XDR-TB cases could improve global surveillance. Following notification, the WHO director-general must
determine whether notified events actually constitute public health emergencies of international concern and, if so,
must issue temporary recommendations guiding countries
in their response.22
A WHO task force argued that XDR-TB does not constitute a public health emergency of international concern because such a declaration is “really only intended for outbreaks of acute disease, rather than the ‘acute-on-chronic’
situation of . . . XDR-TB.”23 This interpretation is questionable because the IHR 2005 never uses “acute disease” to define its scope. The reaction to Speaker’s case indicates that
XDR-TB is a dangerous pathogen of global concern. XDR-TB
may be an early test case for how WHO and its member states
apply the IHR 2005.
(Reprinted) JAMA, July 4, 2007—Vol 298, No. 1 85
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Second, Speaker’s isolation order requires examination
of whether compulsory measures may be increasingly necessary to contain XDR-TB around the world.24,25 The IHR
2005 recognizes the need for such measures but requires
that countries apply them in a manner consistent with scientific, public health, and human rights principles.22
Addressing the Global Crisis of XDR-TB
Speaker’s travails partially lifted the veil on the global XDR-TB
crisis. How do the United States and the international community confront the emergence of XDR-TB around the
world? A host of challenges exist, including improving surveillance, designing nonpharmacological interventions that
protect public health while respecting human rights, inventing better diagnostics, managing XDR-TB’s deadly synergy with HIV/AIDS, creating new antibiotics that are available in developing countries, and building health system
capacities to handle the burden of XDR-TB. The grim march
of TB from MDR-TB to XDR-TB does not bode well for
achieving the changes needed to produce robust global responses to the extremely drug-resistant manifestation of the
white plague. XDR-TB threatens global health, challenges
the rule of law, and requires improved international cooperation.
Financial Disclosures: None reported.
REFERENCES
1. Schwartz J. Tangle of conflicting accounts in TB patient’s odyssey. New York
Times. June 2, 2007:1A.
2. Brown D, Hsu S. Officials detail errors in TB case; travel followed lack of cooperation, late reaction, weak safeguards. Washington Post. June 7, 2007:A06.
3. Speaker A. Transcript of interview with “Good Morning America.” June 1 and 4,
2007. http://www.transcripts.tv/good-morning-america.cfm. Accessed June 8, 2007.
4. Recent Case of Extensively Drug Resistant TB: CDC’s Public Health Response:
Statement to the US House of Representatives Committee on Homeland Security,
110th Cong, 1st Sess ( June 6, 2007) (testimony of Julie Gerberding, MD, MPH,
director of the CDC). http://www.hhs.gov/asl/testify/2007/06/t20070606a
.html. Accessibility verified June 11, 2007.

5. Interim timeline: actions to protect public health: investigation of U.S. traveler
with XDR TB. http://www.cdc.gov/tb/xdrtb/timeline.htm. Posted June 12, 2007.
Accessed June 12, 2007.
6. CDC. International notes: quarantine measures smallpox—Stockholm, Sweden, 1963. MMWR Morb Mortal Wkly Rep. 1996;45(25):538-545.
7. Markel H. When Germs Travel: Six Major Epidemics That Have Invaded America
Since 1900 and the Fears They Unleashed. New York, NY: Pantheon Books; 2005.
8. CDC. Extensively drug-resistant tuberculosis (XDR TB). April 2007. http://www
.cdc.gov/tb/pubs/tbfactsheets/xdrtb.htm. Accessed June 8, 2007.
9. WHO. Emergence of XDR-TB. http://www.who.int/mediacentre/news/notes
/2006/np23/en/index.html. Accessed June 8, 2007.
10. WHO. XDR-TB Update 2006: message from the WHO Director of Stop TB,
Dr Mario Raviglione. http://www.who.int/tb/xdr/dir_stb_message_25sep06/en
/index.html. Accessed June 8, 2007.
11. Markel H. Quarantine! East European Jewish Immigrants and the New York
City Epidemics of 1892. Baltimore, MD: Johns Hopkins University Press; 1999.
12. White House; Office of Homeland Security. National Strategy for Homeland
Security, July 2002. http://www.whitehouse.gov/homeland/book/nat_strat_hls
.pdf. Accessed June 8, 2007.
13. Gostin LO, Sapsin JW, Teret SP, et al. The Model State Emergency Health Powers Act: planning for and response to bioterrorism and naturally occurring infectious diseases. JAMA. 2002;288(5):622-628.
14. Hodge JG, Gostin LO, Gebbie K, et al. Transforming public health law: the
Turning Point Model State Public Health Act. J Law Med Ethics. 2006;34(1):77-84.
15. Regulations to Control Communicable Diseases. 42 USC §264 (2005).
16. Executive Order 13295: Revised List of Quarantinable Communicable Diseases.
April 4, 2003. http://www.cdc.gov/ncidod/sars/executiveorder040403.htm. Accessibility verified June 11, 2007.
17. O’Connor v Donaldson, 422 US 563, 580 (1975).
18. Green v Edwards, 263 SE2d 661 (WVa 1980).
19. Control of communicable diseases. Fed Regist. 2005;70(229):71891-71948.
To be codified at 42 CFR §70, 71.
20. Equal Employment Opportunity Commission v Arabian American Oil Co, 499
US 244 (1991).
21. Committee on Measures to Enhance the Effectiveness of the CDC Quarantine Station Expansion Plan for U.S. Ports of Entry. Quarantine Stations at Ports
of Entry: Protecting the Public’s Health. Washington, DC: National Academies Press;
2006.
22. World Health Assembly. Revision of the International Health Regulations. 58th
World Health Assembly. Geneva, Switzerland: World Health Organization; May
23, 2005. http://www.who.int/gb/ebwha/pdf_files/WHA58/WHA58_3-en
.pdf. Accessed June 8, 2007.
23. WHO Global Task Force on XDR-TB. Update: February 2007. http://www
.who.int/tb/xdr/globaltaskforce_update_feb07.pdf. Accessed June 8, 2007.
24. Singh JA, Upshur R, Padayatchi N. XDR-TB in South Africa: no time for denial
or complacency. PLoS Med. 2007;4(1):e50. http://www.pubmedcentral.nih.gov
/articlerender.fcgi?artid=1779818. Accessed June 8, 2007.
25. WHO. WHO guidance on human rights and involuntary detention for XDR-TB
control. January 24, 2007. http://www.who.int/tb/xdr/involuntary_treatment
/en/index.html. Accessed June 8, 2007.

Public Health Benefits of Recent Litigation
Against the Tobacco Industry
Jon S. Vernick, JD, MPH
Lainie Rutkow, JD, MPH
Stephen P. Teret, JD, MPH

A

S WITH LAWSUITS INVOLVING OTHER DANGEROUS

products, litigation against the tobacco industry
can serve several important functions. Lawsuits can
compensate individuals harmed by the product and
can serve a public health purpose by encouraging manufacturers to change their products, sales, or marketing strat86
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egies to reduce risks. Information obtained in litigation also
can be used to support future regulatory action.1
Litigation against the tobacco industry has met with mixed
success.2 Between 1954 and 1994, private citizens filed more
than 800 lawsuits against tobacco manufacturers.3 The tobacco companies achieved great success in court during this
time by challenging the science that tied smoking to negaAuthor Affiliations: Center for Law and the Public’s Health, Johns Hopkins Bloomberg
School of Public Health, Baltimore, Maryland.
Corresponding Author: Jon S. Vernick, JD, MPH, Center for Law and the Public’s
Health, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Baltimore, MD 21205 (jvernick@jhsph.edu).
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